Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden. The first year

European Journal of Health Economics

Volumn 5, Issue 4, 2004, Pages 351-356

  Ramsberg, Joakim ^a   Odeberg, Stefan ^a   Engström, Andreas ^a   Lundin, Douglas ^a  

^a Pharmaceutical Benefits Board   (Sweden)

Author keywords

Cost per quality adjusted life year; Cost effectiveness; Method; Reimbursement

Indexed keywords

BOARD OF TRUSTEES; CORRELATION ANALYSIS; DRUG INDUSTRY; ECONOMIC ASPECT; EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; INTERMETHOD COMPARISON; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REVIEW; SWEDEN; VALIDATION PROCESS; ARTICLE; COST BENEFIT ANALYSIS; HUMAN; PHARMACOECONOMICS;

COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; QUALITY-ADJUSTED LIFE YEARS; SWEDEN;

EID: 17444373096     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-004-0246-1     Document Type: Review

References (9)

1. Bradley CA, Iskedjian M, Lancot KL et al. (1995) Quality assessment of economic evaluations in selected pharmacy, medical and health economics journals. Ann Pharmacother 29:681-689
2. Kumar, Ritesh N, Raisch, Dennis W, Borrego, Matthew E (2002) Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia. Expert Rev Pharmacoecon Outcomes Res 2:565-575
3. Iskedjian M, Trakas K, Bradley CA et al. (1997) Quality assessment of economic evaluations published in pharmacoeconomics. Pharmacoeconomics 12:685-694
4. Baladi J-F, Menon D, Otten N (1998) Use of economic evaluation guidelines: 2 years' experience in Canada. Health Econ 7:221-227
5. Anis AH, Gagnon Y (2000) Using economic evaluations to make formulary coverage decisions: so much for guidelines. Pharmacoeconomics 18:55-62
6. Hill SR, Mitchell AS, Henry DA (2000) Problems with the interpretation of pharmaeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2116-21
7. Pharmaceutical Benefits Board (2003) General guidelines for economic evaluations from the Pharmaceutical Benefits Board. LFNAR 2003, 2. Available athttp://www.lfn.se/documents/ln%20English/ENG_lfnar2003-eng.pdf. Accessed November 18
8. Ofman, Joshua J, Sullivan, Sean D, Neumann, Peter J, Chiou, Chiun-Fang, Henning, James M, Wade, Sally W, Hay JW (2003) Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Managed Care Pharm 9:53-61
9. Philips Z, Ginelly L, Sculpher M, Claxton K (2003) A review of guidelines for good practice in decision-analytic modelling in health technology assessment. Presented at the Society for Medical Decision Making, 25th annual meeting. October, Chicago